Viking Therapeutics, Inc.
VKTX
$24.99
-$0.67-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.69% | 10.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.96% | 26.49% | |||
| Operating Income | -19.96% | -26.49% | |||
| Income Before Tax | -28.83% | -42.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.83% | -42.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.83% | -42.01% | |||
| EBIT | -19.96% | -26.49% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -28.01% | -41.44% | |||
| Normalized Basic EPS | -28.02% | -40.79% | |||
| EPS Diluted | -28.01% | -41.44% | |||
| Normalized Diluted EPS | -28.02% | -40.79% | |||
| Average Basic Shares Outstanding | 0.65% | 0.39% | |||
| Average Diluted Shares Outstanding | 0.65% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||